RESEARCH INTEREST
The Advanced Hematology Therapies Group at the Princess Hospital Research Institute is dedicated to promoting clinical, epidemiological, and translational research on benign and malignant hematological diseases, as well as the use of peripheral blood and bone marrow cells as a therapeutic source for treatments. The group’s scope of activity is broad, reflecting the diverse interests of its members, and ranges from genetic and molecular studies to the development of new drugs for blood disorders and advanced therapeutic approaches, such as hematopoietic transplantation and cell therapies, including CAR-T cells. The group has a special interest in the following areas:
• Study of the efficacy and safety of new drugs with novel mechanisms of action in malignant hematologic neoplasms and benign blood disorders.
• Advanced therapies using CAR-T cells (chimeric antigen receptor T-cells) and other cellulartherapies.
• Immunological, molecular, and genetic studies in hematologic neoplasms.
• Analysis of new approaches to improve clinical outcomes of stem cell transplantation, including new donor sources, such as haploidentical or unrelated donors, and new strategies to prevent graft-versus-host disease.
• Analysis of infectious complications in immunocompromised hematology patients.
• Epidemiological studies of blood disorders, primarily neoplasms: incidence, prevalence, and mortality.
• Analysis of hypercoagulable states and the use of new anticoagulants for prevention and treatment.
• New strategies in apheresis and transfusion medicine.
Dr. Alegre Amor heads the Hematopoietic Transplantation, CAR-T, and Advanced Therapies Program at La Princesa Hospital. Dr. Alegre and his team have focused their clinical research on all the areas mentioned, participating over the past five years in numerous clinical trials on hematologic malignancies—primarily multiple myeloma, acute and chronic leukemias, lymphomas, and myelodysplastic syndromes—using new drugs. Over the next five years, the objectives are to continue these translational studies and also to participate in competitive grant calls with innovative projects in all the aforementioned areas, which could encompass all hematologic malignancies treated by our group. As a reference center designated by the Ministry of Health for CAR-T therapies and a member of the CERTERA Consortium Network, the group will conduct CAR-T clinical trials for hematologic and non-hematologic disorders. Additionally, other plans include establishing studies on molecular genetics, immunotherapy, epidemiology, pharmacology, comorbidity, long-term follow-up, and quality of life for these complex diseases.
García-Gutiérrez V, Martinez-Trillos A, Lopez Lorenzo JL, Bautista G, Martin Mateos ML, Alvarez-Larrán A, Iglesias Pérez A, Romo Collado A, Fernandez A, Portero A, Cuevas B, Ruiz C, Romero E, Ortega F, Mata I, Tallón J, García Garay Mdel C, Ramirez Sánchez MJ, de Las Heras N, Giraldo P, Bobillo S, Guinea JM, Deben G, Valencia S, Sebrango A, Boqué C, Maestro B, Steegmann JL. Bosutinib shows low cross intolerance, in chronic myeloid leukemia patients treated in fourth line. Results of the Spanish compassionate use program. Am. J. Hematol. 2015. 90: 429-433. FI: 3,798(Q1). PMID: 25683327. DOI: 10.1002/ajh.23973.
García-Gutiérrez V, Puerta JM, Maestro B, Casado Montero LF, Muriel A, Molina Hurtado JR, Perez-Encinas M, Moreno Romero MV, Suñol PB, Sola Garcia R, De Paz R, Ramirez Sanchez MJ, Osorio S, Mata Vazquez MI, Martinez López J, Sastre JL, Portero Mde L, Bautista G, Duran Nieto MS, Giraldo P, Jimenez Jambrina M, Burgaleta C, Ruiz Aredondo J, Peñarrubia MJ, Requena MJ, Fernández Valle Mdel C, Calle C, Paz Coll A, Hernández-Rivas JÁ, Franco Osorio R, Cano P, Tallón Pérez D, Fernández de la Mata M, Garrido PL, Steegmann JL. Do chronic myeloid leukemia patients with late “warning” responses benefit from “watch and wait” or switching therapy to a second generation tyrosine kinase inhibitor?. Am. J. Hematol. 2014. 89: 206-211. FI: 3,798(Q1). PMID: 25059397. DOI: 10.1002/ajh.23816.
Jabbour E, Kantarjian HM, Saglio G, Steegmann JL, Shah NP, Boqué C, Chuah C, Pavlovsky C, Mayer J, Cortes J, Baccarani M, Kim DW, Bradley-Garelik MB, Mohamed H, Wildgust M, Hochhaus A. Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION). Blood 2014. 123: 494-500. FI: 10,452(Q1). PMID: 24311723. DOI: 10.1182/blood-2013-06-511592.
Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF, Cervantes F, Clark RE, Cortes JE, Guilhot F, Hjorth-Hansen H, Hughes TP, Kantarjian HM, Kim DW, Larson RA, Lipton JH, Mahon FX, Martinelli G, Mayer J, Müller MC, Niederwieser D, Pane F, Radich JP, Rousselot P, Saglio G, Saußele S, Schiffer C, Silver R, Simonsson B, Steegmann JL, Goldman JM, Hehlmann R. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood 2013. 122: 872-884. FI: 9,775(Q1). PMID: 23803709. DOI: 10.1182/blood-2013-05-501569.
Hoffmann VS, Baccarani M, Lindoerfer D, Castagnetti F, Turkina A, Zaritsky A, Hellmann A, Prejzner W, Steegmann JL, Mayer J, Indrak K, Colita A, Rosti G, Pfirrmann M. The EUTOS prognostic score: review and validation in 1288 patients with CML treated frontline with imatinib. Leukemia 2013. 27: 2016-2022. FI: 9,379(Q1). PMID: 23752173. DOI: 10.1038/leu.2013.171.
